Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226315 · ClinicalTrials.gov registry record
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
A clinical trial, sponsored by Sequenom.
- Terminated
- Registry status
- 50
- Enrollment target
NCT02226315: Clinical Trial study, sponsored by Sequenom.
NCT02226315 is a clinical trial that was terminated before completion, run by Sequenom. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226315 was terminated before completion, sponsored by Sequenom.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.
Primary Outcome
Results of the MaterniT21 PLUS LDT will be compared to the pregnancy outcome data obtained from the patient
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-09 |
Why NCT02226315 stopped before completion
NCT02226315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02226315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02226315 about?
NCT02226315 is a clinical study titled "Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies". This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk fo...
What is the current status of trial NCT02226315?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2014-08. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT02226315?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia